News & Publications
Press Releases
-
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
March 7, 2023 by NanOlogy
-
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
December 20, 2022 by NanOlogy
-
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
November 11, 2022 by NanOlogy
-
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
September 20, 2022 by NanOlogy
-
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
August 1, 2022 by NanOlogy
NanOlogy in the News
-
OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
September 16, 2021 by NanOlogy
-
Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 16, 2021 by NanOlogy
-
JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
March 26, 2021 by NanOlogy
-
Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
January 9, 2020 by NanOlogy
-
Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
May 7, 2019 by NanOlogy
Presentations
- DDW 2023 Poster: Intracystic Injection of Large Surface Area Microparticle Paclitael for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol
- NanOlogy General Presentation (January 2023)
- DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
Publications
- Diagnostics: A Review of Endoscopic Ultrasound-Guided Chemoablative Techniques for Pancreatic Cystic Lesions
- Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts
- The Journal of Urology : Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer
- Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
- Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery
Upcoming NanOlogy Events
- June 2 : 9th Annual Immuno-Oncology Innovation Forum | Chicago
- June 2-6 : ASCO 2023 – American Society of Clinical Oncology | Chicago
- August 24-26 : AABIP – 6th Annual Conference of American Association for Bronchial and Interventional Pulmonology | Chicago
- September 27-30 : AACR Special Conference: Pancreatic Cancer | Boston
- November 1-5 : SITC – 38th Annual Meeting Society for Immunotherapy of Cancer | San Diego
- December 1-3 : IASLC 2023 – North American Conference on Lung Cancer| Chicago
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
